The effects of the NICE Technology Appraisal 121 (Gliadel and Temozolomide) on survival in high-grade glioma

British Journal of Neurosurgery

Volumn 26, Issue 6, 2012, Pages 818-822

  Barr, James Geoffrey ^a   Grundy, Paul L ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Carmustine; High grade glioma; NICE; Survival; Temozolomide

Indexed keywords

CARMUSTINE; TEMOZOLOMIDE;

ADULT; ANAPLASTIC OLIGOASTROCYTOMA; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; GIANT CELL GLIOBLASTOMA; GLIOBLASTOMA; GLIOMA; GLIOSARCOMA; HUMAN; MAJOR CLINICAL STUDY; MEDICAL AUDIT; OLIGODENDROGLIOMA; PRIORITY JOURNAL; REOPERATION; RETROSPECTIVE STUDY; UNITED KINGDOM;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CARMUSTINE; COMBINED MODALITY THERAPY; DACARBAZINE; DECANOIC ACIDS; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; POLYESTERS; TREATMENT OUTCOME;

EID: 84870262611     PISSN: 02688697     EISSN: 1360046X     Source Type: Journal    
DOI: 10.3109/02688697.2012.697221     Document Type: Article

References (25)

1. Fisher PG, Buf er PA. Malignant gliomas in 2005: Where to go from here? JAMA 2005;293:615-17. (Pubitemid 40171245)
2. GLOBOCAN. Worldwide Incidence and Mortality of Cancer, 2002 [computer program]. Lyon, France: IARC Press, 2002.
3. Parkin DM, Whelan SL, Ferlay J, Teppo L, Tomas DB. Cancer in Five Continents, Vol 5. Lyon, France: IARC Press, 2002.
4. Brada M, Yung WKA. Clinical tr ial end points in malignant glioma: Need for effective trial design strategy. Semin Oncol 2000;27(Suppl 6):11-19. (Pubitemid 30390230)
5. Hildebrand J, DeWitte O, Dietrich PY, de Tribolet N. Management of malignant brain tumors. Eur. Neurol 1997;38:238-53. (Pubitemid 27429872)
6. Giese A, Westphal M. Glioma invasion in the central nervous system. Neurosurgery 1996;39:235-52. (Pubitemid 26251544)
7. Cairncross JG, Macdonald DR, Ramsay DA. Aggressive oligodendroglioma: A chemosensitive tumor. Neurosurgery 1992;31:78-82.
8. Fine HA, Dear KBG, Loefer JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant glioma in adults. Cancer 1993 ; 71:2585-97. (Pubitemid 23100496)
9. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980;303:1323-9. (Pubitemid 11194457)
10. Fung LK, Ewend MG, Sills A, et al. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res 1998;58:672-84. (Pubitemid 28099477)
11. Brem H, Tamargo RJ, Olivi A, et al. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. J Neurosurg 1994;80:283-90. (Pubitemid 24036500)
12. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003;5:79-88. (Pubitemid 36422560)
13. Westphal M, Ram Z, Riddle V, Hilt D, BorteyE;ExecutiveCommittee of the Gliadel Study Group. Gliadel wafer in initial surgery for malignant glioma: Long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 2006;148:269-75. (Pubitemid 43341024)
14. Attenello FJ, Mukherjee D, Datoo G, et al. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: A 10-year institutional experience. Ann Surg Oncol 2008;15:2887-93.
15. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and ef cacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995;345:1008-12.
16. Sabel M, Giese A. Safety prof le of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience. Curr Med Res Opin 2008;24:3239-57.
17. NICE: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma. http://guidance.nice.org.uk/index.jsp?action = download&o = 34050. Accessed 22/12/10.
18. McGirt MJ, Tan KD, Weingart JD, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg2009;110:583-8.
19. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96. (Pubitemid 40349501)
20. La Rocca RV, Hodes J, Villanueva WG, et al. A Phase II study of radiation with concomitant and then sequential temozolomide (TMZ) in patients with newly diagnosed supratentorial high-grade malignant glioma who have undergone surgery with carmustine (BCNU) wafer insertion. Soc Neuro-Oncol Florida 2006;8:445, Abstract TA-2.
21. Af ronti ML, Heery CR, Herndon JE 2nd et al. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer 2009;115:3501-11.
22. McGovern PC, Lautenbach E, Brennan PJ, et al. Risk factors for postcraniotomy surgical site infection after 1, 3-bis 2-chloroethyl.-1- nitrosourea Gliadel wafer placement. Clin Infect Dis 2003;36:759-65. (Pubitemid 36337980)
23. Brem H, Piantadosi S, Burger PC, et al. Placebo-controllefd trial of safety and ef cacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 1995;345:1008-12.
24. 6- methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008;26:4189-99.
25. 6 BG) plus BCNU versus RT and BCNU alone for newly diagnosed GBM. J Clin Oncol 2006;24(Suppl):1512.